Slowdown in approvals not safety related: FDA
FDA Office of New Drugs director John Jenkins said concerns over drug safety and "gaming" of the review clock were not to blame for a significant drop in first-cycle approvals, instead attributing the decline to historical fluctuations.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.